Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
← catalyst calendarSponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,143actual
Sites
50
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-28 | actual | When the study began enrolling |
| Primary completion | 2025-12-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Resistant Hypertension
- Hypercortisolism
Primary outcome
what the primary-completion date above is the date OFTo assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension.
measured From enrollment to the end of the study which is approximately 4 weeks.
Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed